Lisa Urquhart

April should mark the approval of some of the biggest drugs of 2022, including Alnylam’s vutrisiran, while TG will hope to be spared pain at the PI3K adcom.

US FDA approval tracker: March 2022 - Evaluate Pharma

New extended consensus forecasts from Evaluate Pharma show Roche edged out of first place by Abbvie as new blood replaces Humira.

Intercept looks for redemption in Nash in the third quarter, while Kymera, Zealand and Anavex hope for share price boosts.

Humanigen is left nursing Covid losses  Vantage

Cincor’s blood pressure win quickens investors’ pulses  Evaluate Pharma CinCor Pharma (NASDAQ:CINC) Hits New 1-Year High at $40.00  Defense World CinCor Pharma (NASDAQ:CINC) Hits New 52-Week High at $40.00  ETF Daily News Forget What the Analysts Say and Check out Trade Data for CinCor Pharma Inc. (CINC)  Invest Chronicle A Technical View of the CinCor Pharma Inc. (CINC)  The Fosters Leader View Full Coverage on Google News

Clovis's story ends at chapter 11 - Evaluate Pharma

Clovis's story ends at chapter 11 - evaluate.com

Biontech joins artificial intelligence race through Instadeep - Evaluate Pharma

Biontech joins artificial intelligence race through Instadeep - Evaluate Pharma

Medtech venture funding started strongly in 2022, but a slump in the fourth quarter could give rise to concern.